Ming Yu seeks a share of the drug sector limelight
Led by a former research chief at drugs giant Hengrui, the Chinese biotech can boast solid credentials and big-name backers as it positions for a Hong Kong IPO Key Takeaways:…
Recent Articles
RELATED ARTICLES
-
Hengrui Pharma targets obesity drug launch after test success
1278.HK600276.SHG -
Precision cancer drugs show promise for Kelun-Biotech
6990.HK
-
CSPC feels the pain from sweeping cuts in drug prices
1093.HK
-
So big but so what? Innovent’s license deal fails to excite investors
1801.HK
- Obesity drug maker Sciwind targets IPO, with heavyweight backers
- Armed with AstraZeneca deal, Eccogene files for Hong Kong IPO
-
XtalPi scores landmark deal for AI drug discovery
2228.HK
